Treatment of erectile dysfunction due to C677T mutation of the MTHFR gene with vitamin B6 and folic acid in patients non responders to PDE5i

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 1, 2010, Pages 216-223

  Lombardo, Francesco ^a   Tsamatropoulos, Petros ^a   Piroli, Emanuela ^a   Culasso, Franco ^a   Jannini, Emmanuele Angelo ^b   Dondero, Franco ^a   Lenzi, Andrea ^a   Gandini, Loredana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Endothelial dysfunction; Hyperhomocysteinemia; PDE5I; Rectile dysfunction; Sildenafil citrate

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOSINE; FOLIC ACID; HOMOCYSTEINE; PHOSPHODIESTERASE V INHIBITOR; PYRIDOXINE; SILDENAFIL; THYMINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TREATMENT FAILURE; ERECTILE DYSFUNCTION; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 74049112618     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01463.x     Document Type: Article

References (41)

1. Selhub J, Miller JW. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by s-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992, 55:131-8.
2. Lee JH, Ngengwe R, Jones P, Tang F, O'Keefe JH. Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol 2008, 15:800-3.
3. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363-75.
4. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042-50.
5. Maitland-van der Zee AH, Lynch A, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Ford CE, Eckfeldt JH. MTHFR 677C>T, MTHFR 1298 A>C, and CBSins and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: The GenHAT study. Pharmacogenet Genomics 2008, 18:651-6.
6. Bos MJ, van Goor ML, Koudstaal PJ, Dippel DW. Plasma homocysteine is a risk factor for recurrent vascular events in young patients with an ischaemic stroke or TIA. J Neurol 2005, 252:332-7.
7. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993, 270:2693-8.
8. Norlund L, Grubb A, Fex G, Leksell H, Nilsson JE, Schenck H, Hultberg B. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 1998, 36:175-8.
9. Van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant 2006, 21:1161-6.
10. Kang SS, Passen EL, Ruggie N, Wong PW, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993, 88:1463-9.
11. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR Studies Collaboration Group.MTHFR 677C->T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 2002, 288:2023-31.
12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-3.
13. Kloner RA. Erectile dysfunction as a predictor of cardiovascular disease. Int J Impot Res 2008, 20:460-5.
14. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 2002, 4:397-401.
15. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666-72.
16. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999, 54:346-51.
17. Cormio L, Bettocchi C, Ricapito V, Zizzi V, Traficante A, Selvaggi FP. Resistance index as a prognostic factor for prolonged erection after penile dynamic colour Doppler ultrasonography. Eur Urol 1998, 33:94-7.
18. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, Frajese G, Fabbri A. Androgens and penile erection: Evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol 2000, 53:517-22.
19. Mancini M, Bartolini M, Maggi M, Innocenti P, Forti G. The presence of arterial anatomical variations can affect the results of duplex sonographic evaluation of penile vessels in impotent patients. J Urol 1996, 155:1919-23.
20. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J. Folate induces endothelial function in coronary artery disease: An effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001, 21:1196-202.
21. Permpongkosol S, Kongkakand A, Ratana-Olarn K, Tantiwong A, Tantiwongse K. Thai Erectile Dysfunction Epidemiological Study Group: Increased prevalence of erectile dysfunction (ED): Results of the second epidemiological study on sexual activity and prevalence of ED in Thai males. Aging Male 2008, 11:128-33.
22. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998, 49:31-62.
23. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997, 90:1-11.
24. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessement of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-57.
25. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: The atherosclerosis risk in communities study. Circulation 1993, 87:1107-13.
26. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis. N Engl J Med 1995, 332:286-91.
27. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G. The European Concerted Action Project: Plasma homocysteine as a risk factor for vascular disease. JAMA 1977, 277:1775-81.
28. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996, 98:5-7.
29. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987, 262:10098-103.
30. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991, 88:1785-9.
31. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 1995, 41:361-6.
32. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986, 77:1370-6.
33. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993, 91:308-18.
34. Foresta C, Caretta N, Lana A, Cabrelle A, Palù G, Ferlin A. Circulating endothelial progenitor cells in subjects with erectyle dysfunction. Int J Impot Res 2005, 17:288-90.
35. Esposito K, Ciotola M, Maiorino MI, Giugliano F, Autorino R, De Sio M, Jannini EA, Lenzi A, Giugliano D. Circulating CD34+KDR+ endothelial progenitors cells correlate with erectile function and endothelial function in overweight men. J Sex Med 2009, 6:107-14.
36. Costa C, Virag R. The endothelial-erectile dysfunction connection: An essential update. J Sex Med 2009, Jun 11 [Epub ahead of print
37. Demir T, Comlekçi A, Demir O, Gülcü A, Calýpkan S, Argun L, Seçil M, Yepil S, Esen A. Hyperhomocysteinemia: A novel risk factor for erectile dysfunction. Metabolism 2006, 55:1564-8.
38. Al-Hunayan A, Thalib L, Kehinde EO, Asfar S. Hyperhomocysteinemia is a risk factor for erectile dysfunction in men with adult-onset diabetes mellitus. Urology 2008, 71:897-900.
39. Lombardo F, Sgrò P, Gandini L, Dondero F, Jannini EA, Lenzi A. Might erectile dysfunction be due to the thermolabile variant of methylenetetrahydrofolate reductase? J Endocrinol Invest 2004, 27:883-5.
40. Khan MA, Thompson CS, Emsley AM, Mumtaz FH, Mikhailidis DP, Angelini GD, Morgan RJ, Jeremy JY. The interaction of homocysteine and copper markedly inhibits the relaxation of rabbit corpus cavernosum: New risk factors for angiopathic erectile dysfunction? BJU Int 1999, 84:720-4.
41. Jones RW, Jeremy JY, Koupparis A, Persad R, Shukla N. Cavernosal dysfunction in a rabbit model of hyperhomocysteinaemia. BJU Int 2005, 95:125-30.